Key facts
- Variantyx’s last known valuation is $98.0M (Apr 2024).
- It has raised $175.3M across 1 recorded rounds; the latest was Early Stage VC ($15.6M) in Feb 2021.
- Notable investors include OrbiMed, Pitango Venture Capital, Bosch Ventures, Peregrine Ventures, New Era Capital Partners — 11 tracked in total.
- Variantyx has filed 1 Form D with the SEC, most recently Mar 2021 ($15.6M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Variantyx
Funding rounds
1 roundsAbout Variantyx
Developer of genetic testing platform designed to improve diagnosis and personalized medicine for rare genetic disorders, reproductive genetics and precision oncology. The company's platform features advanced laboratory technology, proprietary AI and machine learning analytical tools, flexible reflex testing options, and streamlined patient billing policies, enabling healthcare providers and patients to access detailed genomic analysis that supports clinical decision-making and shortens the diagnostic process.
- Sector
- Healthcare
- HQ
- Framingham, MA, United States
- Founded
- 2014
- Employees
- 194
- Website
- variantyx.com/
- Ownership
- Privately Held (backing)
Variantyx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Variantyx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Variantyx in its N-PORT filings yet. We sweep new filings monthly.